VENZIP XL 75mg prolonged-release capsules, hard

Страна: Великобритания

Язык: английский

Источник: myHealthbox

Активный ингредиент:

venlafaxine (as hydrochloride)

Доступна с:

Milpharm Limited

код АТС:

NO6AX16

ИНН (Международная Имя):

venlafaxine (as hydrochloride)

дозировка:

75mg

Фармацевтическая форма:

Prolonged-release tablet, hard

Администрация маршрут:

Oral use

Штук в упаковке:

7, 10, 14, 20, 28, 30, 50, 56, 60, 90, 98 and 100 capsules

Тип рецепта:

POM - Prescription Only Medicine

Производитель:

APL Swift Services (Malta) Limited

Терапевтическая группа:

Antidepressants, Other antidepressants

Терапевтические показания :

Treatment of major depressive episodes. For prevention of recurrence of major depressive episodes. Treatment of generalised anxiety disorder. Treatment of social anxiety disorder. Treatment of panic disorder, with or without agoraphobia.

Статус Авторизация:

Authorised

Дата Авторизация:

2015-01-23

тонкая брошюра

Black
VENZIP XL

prolonged-release capsules, hard
P150XXXX
9596
VENZIP XL

prolonged-release capsules, hard
P150XXXX
9596
PACKAGE LEAFLET : INFORMATION FOR THE USER
VENZIP XL 75 MG PROLONGED-RELEASE CAPSULES, HARD
VENZIP XL 150 MG PROLONGED-RELEASE CAPSULES, HARD 
Venlafaxine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT 
CONTAINS IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm 
them, even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible 
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1. 
What VENZIP XL is and what it is used for 
2. 
What you need to know before you take VENZIP XL
3. 
How to take VENZIP XL
4. 
Possible side effects
5. 
How to store VENZIP XL
6. 
Contents of the pack and other information 

1.  WHAT VENZIP XL IS AND WHAT IT IS USED FOR 
VENZIP XL is an antidepressant that belongs to a group of medicines
called serotonin 
and norepinephrine reuptake inhibitors (SNRIs). This group of
medicines is used to treat 
depression and other conditions such as anxiety disorders. It is
thought that people who are 
depressed and/or anxious have lower levels of serotonin and
noradrenaline in the brain. It is 
not fully understood how antidepressants work, but they may help by
increasing the levels of 
serotonin and noradrenaline in the brain. 
VENZIP XL is a treatment for adults with depression. It is also a
treatment for adults with 
the following anxiety disorders: generalised anxiety disorder, social
anxiety disorder (fear 
or avoidance of social situations) and panic disorder (panic
attacks). Treating depression or 
anxiety disorders properly is important to help you get better. If it
is not tre

Характеристики продукта

SUMMARY OF PRODUCT CHARACTERISTICS 

1 
NAME OF THE MEDICINAL PRODUCT 
VENZIP XL 75 mg prolonged-release capsules, hard 

2 
QUALITATIVE AND QUANTITATIVE COMPOSITION 
Each prolonged-release capsule contains 75 mg of
venlafaxine (as hydrochloride). 
Excipient with known effect: 
Each capsule contains 87.1 mg sucrose. 
_ _
For the full list of excipients, see section 6.1. 

3 PHARMACEUTICAL 
FORM 
Prolonged-release capsule, hard 

White to off-white spherical to oval pellets filled in Empty hard
gelatin capsule shell 
(size ‘1’) of Opaque Peach color cap and Opaque Peach color
body imprinted with 
“E” on cap and “74” on the body with edible black ink. 

4 CLINICAL 
PARTICULARS 

4.1 THERAPEUTIC 
INDICATIONS 
Treatment of major depressive episodes.  
For prevention of recurrence of major depressive episodes. 
Treatment of generalised anxiety disorder. 
Treatment of social anxiety disorder. 
_ _
Treatment of panic disorder, with or without agoraphobia. 

4.2 
POSOLOGY AND METHOD OF ADMINISTRATION 
_Major depressive episodes _
The recommended starting dose for
prolonged-release venlafaxine is 75 mg given 
once daily. Patients not responding to the initial 75
mg/day dose may benefit from 
dose increases up to a maximum dose of 375
mg/day. Dosage increases can be made 
at intervals of 2 weeks or more. If clinically warranted due
to symptom severity, dose 
increases can be made at more frequent intervals, but not
less than 4 days. 

Because of the risk of dose-related adverse effects, dose
increments should be made 
only after a clinical evaluation (see section 4.4). The lowest
effective dose should be 
maintained. 

Patients should be treated for a sufficient period of time,
usually several months or 
longer. Treatment should be reassessed regularly on a case-by-case
basis. Longer-
term treatment may also be appropriate for preventio